Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535267 | 0.79 | KMT2A (0.56) | KMT2ANPC1RAB9AF2RL1HTT | |
| SCHEMBL27550242 | 0.77 | PDE10A (0.55) | KMT2ARAB9AHTTSMN1; SMN2PDE10A | |
| SCHEMBL653441 | 0.76 | RAB9A (0.69) | KMT2ANPC1RAB9AF2RL1HTT | |
| SCHEMBL27576939 | 0.75 | CCND3 (0.64) | KMT2ANPC1RAB9APDE10ACCND3 | |
| SCHEMBL7193170 | 0.75 | KMT2A (0.63) | KMT2ANPC1RAB9AF2RL1HTT | |
| SCHEMBL11173816 | 0.75 | KDM4E (0.60) | KMT2ANPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL6795776 | 0.75 | KMT2A (0.58) | KMT2ANPC1RAB9AF2RL1HTT | |
| SCHEMBL27805818 | 0.74 | KMT2A (0.77) | KMT2ANPC1RAB9AF2RL1HTT | |
| Phenanthrene SCHEMBL18789472 | 0.74 | KMT2A (0.46) | KMT2ANPC1RAB9AF2RL1HTT | |
| SCHEMBL8776502 | 0.74 | HTT (0.61) | KMT2AHTTSMN1; SMN2PDE10AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718576-B2 | Peroxide-based chemiluminescent assays and chemiluminescent compounds used therein | WALDROP III ALEXANDER A | 2010-05-18 | — | — | US | disclosed |
| EP-1019379-B1 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | MAINE MEDICAL CT (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20030219844-A1 | Peroxide-based chemiluminescent assays and chemiluminescent compounds used therein | MAINE MEDICAL CENTER | 2003-11-27 | — | — | US | disclosed |
| EP-1019379-A4 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | MAINE MEDICAL CT (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-1019379-A1 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | Maine Medical Center (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999009012-A1 | PEROXIDE-BASED CHEMILUMINESCENT ASSAYS AND CHEMILUMINESCENT COMPOUNDS USED THEREIN | MAINE MEDICAL CENTER (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219844-A1 | Peroxide-based chemiluminescent assays and chemiluminescent compounds used therein | CBR1, CBR3, NR2E3 | KMT2A 3611/4885NPC1 2485/4885RAB9A 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.